HCV InfectionPhase 1NCT00895102
Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy Volunteers
A Phase 1 study testing ABT-333 Tablet and ABT-333 Capsule in people with HCV Infection, run by Abbott at 1 site in United States.
Trial summary
The purpose of this study is to determine the bioavailability, pharmacokinetic and safety profiles of an experimental Hepatitis C virus (HCV) polymerase inhibitor in healthy volunteers. Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- HCV Infection
- What is being tested?
- ABT-333 Tablet and ABT-333 Capsule
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 34 participants
- Where
- 1 siteUnited States
- Study dates
- Apr 2009to Jun 2009
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- overall healthy subjects;
- non-childbearing potential females included
Who cannot join
- history of significant sensitivity to any drug;
- positive test for HAV IgM, HBsAg, anti-HCV Ab or anti-HIV Ab;
- history of gastrointestinal issues or procedures;
- history of seizures, diabetes or cancer (except basal cell carcinoma);
- clinically significant cardiovascular, respiratory (except mild asthma), renal, gastrointestinal, hematologic, neurologic, thyroid, or any uncontrolled medical illness or psychiatric disorder;
- use of tobacco or nicotine-containing products with the 6-month period prior to study drug administration;
Show all 13Show fewer
- donation or loss of 550 mL or more blood volume or receipt of a transfusion of any blood product within 8 weeks prior to study drug administration;
- abnormal screening laboratory results that are considered clinically significant by the investigator;
- current enrollment in another clinical study;
- previous enrollment in this study;
- recent (6-month) history of drug/alcohol abuse that could preclude adherence to the protocol;
- pregnant or breastfeeding female;
- requirement for any OTC and/or prescription medication, vitamins and/or herbal supplements on a regular basis
Trial locations and contacts
1 site in 1 country.
United States1 site
Site Reference ID/Investigator# 19441
Waukegan, Illinois, 60085
About this study
Official title: An Open-Label Randomized, Crossover Study to Evaluate the Bioavailability of ABT-333 Tablets Versus Capsules, and A Double-blind, Randomized, Crossover Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Single Ascending Doses of ABT-333 Tablets Versus Placebo in Healthy Volunteers
The purpose of this study is to determine the bioavailability, pharmacokinetic and safety profiles of an experimental Hepatitis C virus (HCV) polymerase inhibitor in healthy volunteers.
- Conditions
- HCV Infection
- Being tested
- ABT-333 Tablet, Placebo, ABT-333 Capsule
- Keywords
- Bioavailability (BA), Single Ascending Dose (SAD)
- Medical subject headings
- Hepatitis C
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ABT-333 TabletDrug
Also called ABT-333
See Arm Description for more information.
PlaceboDrug
See Arm Description for more information.
ABT-333 CapsuleDrug
See arm description for more information
| Study group | Role | What they receive |
|---|---|---|
| 1. ABT-333 Capsule vs ABT-333 Tablet | Active comparator | 400mg ABT-333 Tablet, QD, single dose vs eight 50mg ABT-333 Capsules, QD, single dose Receives: Drug: ABT-333 Tablet; Drug: ABT-333 Capsule |
| 2. ABT-333 Tablet | Active comparator | ABT-333 400mg Tablet, QD, single ascending doses (1200mg, 1600mg, 2400mg) Receives: Drug: ABT-333 Tablet; Drug: Placebo |
| 3. Placebo | Placebo comparator | Placebo tablets, QD, single ascending doses Receives: Drug: ABT-333 Tablet; Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
To determine relative bioavailability of the ABT-333 tablet formulation compared to the FIH capsule formulation
Measured: 2 days post dosing
To evaluate single dose safety and tolerability of a ABT-333 tablet formulation relative to placebo
Measured: 2 days post dosing
To evaluate single dose pharmacokinetics of a ABT-333 tablet formulation
Measured: 2 days post dosing
Pharmacokinetics
Measured: 5 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 May 2009 (estimated)
- Study startApr 2009
- Primary completionJun 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HCV InfectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 34 participants (actual)
Sponsor and investigators
- Lead sponsor
- Abbott
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Daniel Cohen, MD, Study director, Abbott
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00895102
- Sponsor's protocol ID
- M11-032
- Status last verified
- Sep 2010
- First submitted
- 7 May 2009
- Last updated
- 13 Oct 2010
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Oct 2010. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-Label Randomized, Crossover Study to Evaluate the Bioavailability of ABT-333 Tablets Versus Capsules, and A Double-blind, Randomized, Crossover Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Single Ascending Doses of ABT-333 Tablets Versus Placebo in Healthy Volunteers
- ClinicalTrials.gov ID
- NCT00895102
- Acronym / sponsor ID
- M11-032
- Conditions
- HCV Infection
- Keywords
- Bioavailability (BA), Single Ascending Dose (SAD)
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 34 participants (actual)
- Lead sponsor
- AbbottIndustry (pharma, biotech, devices)
- Study start
- Apr 2009
- Primary completion
- Jun 2009 (actual)
- First posted
- 8 May 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine the bioavailability, pharmacokinetic and safety profiles of an experimental Hepatitis C virus (HCV) polymerase inhibitor in healthy volunteers.
Study design
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| 1. ABT-333 Capsule vs ABT-333 Tablet | Active comparator | Drug: ABT-333 Tablet, Drug: ABT-333 Capsule400mg ABT-333 Tablet, QD, single dose vs eight 50mg ABT-333 Capsules, QD, single dose |
| 2. ABT-333 Tablet | Active comparator | Drug: ABT-333 Tablet, Drug: PlaceboABT-333 400mg Tablet, QD, single ascending doses (1200mg, 1600mg, 2400mg) |
| 3. Placebo | Placebo comparator | Drug: ABT-333 Tablet, Drug: PlaceboPlacebo tablets, QD, single ascending doses |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- overall healthy subjects;
- non-childbearing potential females included
Key exclusion criteria (13 listed)
- history of significant sensitivity to any drug;
- positive test for HAV IgM, HBsAg, anti-HCV Ab or anti-HIV Ab;
- history of gastrointestinal issues or procedures;
- history of seizures, diabetes or cancer (except basal cell carcinoma);
- clinically significant cardiovascular, respiratory (except mild asthma), renal, gastrointestinal, hematologic, neurologic, thyroid, or any uncontrolled medical illness or psychiatric disorder;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ABT-333 TabletAlso: ABT-333See Arm Description for more information. | Drug | 1. ABT-333 Capsule vs ABT-333 Tablet, 2. ABT-333 Tablet, 3. Placebo |
| PlaceboSee Arm Description for more information. | Drug | 2. ABT-333 Tablet, 3. Placebo |
| ABT-333 CapsuleSee arm description for more information | Drug | 1. ABT-333 Capsule vs ABT-333 Tablet |
Primary outcome
To determine relative bioavailability of the ABT-333 tablet formulation compared to the FIH capsule formulation
Time frame: 2 days post dosing
To evaluate single dose safety and tolerability of a ABT-333 tablet formulation relative to placebo
Time frame: 2 days post dosing
To evaluate single dose pharmacokinetics of a ABT-333 tablet formulation
Time frame: 2 days post dosing
Pharmacokinetics
Time frame: 5 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Oct 2010.
Related trials for HCV Infection
RecruitingObservational study
Evaluation of Patients With Liver Disease
Hepatitis D, Hepatitis C
Not yet recruiting
HIV/STI/HCV Testing and Overdose Prevention Among Survivors of Sex Trafficking
HIV Testing, STI
Not yet recruiting
Clinical Study to Evaluate the Performance of the INSTI® HCV Antibody Test for CLIA-Waived Use
HCV Infection
Not yet recruiting
Study to Evaluate the Performance of the INSTI® HCV Antibody Test for Point-of-Care Use in Individuals at Risk for HCV Infection or Presenting With Signs or Symptoms of HCV Infection
HCV Infection
Recruiting
HIV/HBV/HCV Triple Screening in Primary Care
HIV, HBV (Hepatitis B Virus)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Daniel Cohen, MD study director
Abbott
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing ABT-333 Tablet and ABT-333 Capsule in people with HCV Infection, run by Abbott at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Oct 2010. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To determine relative bioavailability of the ABT-333 tablet formulation compared to the FIH capsule formulation (time frame: 2 days post dosing). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2010.